Abstract 1036P
Background
PM1003 is a VHH-based anti-PD-L1 x 4-1BB bispecific antibody that exhibits PD-L1 expression-dependent 4-1BB agonism, with excellent anti-tumor activity and safety in preclinical studies.
Methods
The safety and tolerability of PM1003 in patients (pts) with advanced solid tumors were assessed during dose escalation, and pts with advanced solid tumors positive for PD-L1 expression have been enrolled for assessing anti-tumor activity during dose expansion.
Results
At the data cut-off up to Apr. 19, 2023, 23 pts had been enrolled, with 19 pts for dose escalation (3 pts for each of the 0.02, 0.1, 1, 3, 10 mg/kg dose levels and 4 pts for the 6 mg/kg dose level). All pts had prior 1-6 lines of systemic treatment. Dose-limiting toxicity (DLT) was assessed over 21 days after the first dose followed by dosing Q2W. 4 pts were enrolled for dose expansion (2 pts in 1 mg/kg, 1 patient in each of the 3 and 6 mg/kg dose levels, Q2W). No DLTs were observed during dose escalation. Treatment-related adverse events (TRAEs) occurred in 22 pts (95.7%). The most common TRAEs in pts included anemia (39.1%, Grade≥3 0%), aspartic acid aminotransferase increased (30.4%, Grade≥3 4.3%), white blood cell count decreased (30.4%, Grade≥3 8.7%) and platelet count decreased (30.4%, Grade≥3 0%). For the 1 - 10 mg/kg cohorts, T1/2 was 6.3 - 15.3 days after the first dose. PD-L1 target occupancy approach to saturation at 7 days after the first dose and maintained stable. 18 pts were evaluable for efficacy. The objective response rate was 5.6% and the disease control rate was 44.4%. Preliminary antitumor activity was observed in one PD-L1 positive gastric cancer patient (1 mg/kg, Q2W; TPS=5%, CPS=30) who was heavily treated with chemotherapy, anti-PD-1 and anti-HER2-ADC after surgery. 87.8% of tumor shrinkage was achieved in the target lesion at the first efficacy evaluation (7 weeks) after PM1003 treatment. Partial Response was confirmed at subsequent visits.
Conclusions
PM1003 was well-tolerated at doses up to 10 mg/kg and preliminary antitumor efficacy was observed in a patient with prior anti-PD-1 treatment. Expansion cohorts to evaluate efficacy and further safety in PD-L1-positive pts are ongoing.
Clinical trial identification
ChiCTR2100052887.
Editorial acknowledgement
Legal entity responsible for the study
Biotheus Inc.
Funding
Biotheus Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Presenter: Bilal Krayim
Session: Poster session 19
1344P - A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Presenter: Jorge Nieva
Session: Poster session 19
1345P - Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Presenter: Melissa Junttila
Session: Poster session 19
1346P - Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Presenter: Xiaoyan Li
Session: Poster session 19
1348P - Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Presenter: Yun-Gyoo Lee
Session: Poster session 19
1349P - Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Presenter: Molly Li
Session: Poster session 19
1350P - Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Presenter: Takehiro Tozuka
Session: Poster session 19
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1352P - Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC
Presenter: Ruyun Gao
Session: Poster session 19